BioScience Health Innovations, Inc. SEC 10-Q Report

BioScience Health Innovations, Inc., a company focused on advanced health science innovations, has released its Form 10-Q report for the third quarter of 2025. The report highlights significant financial growth and strategic business developments, reflecting the company's commitment to innovation and market expansion.

Financial Highlights

Revenues: BioScience Health Innovations reported revenues of $1,131,427 for the three months ended September 30, 2025, and $4,115,960 for the nine months ended September 30, 2025. This growth is attributed to increased sales and marketing efforts.

Gross Profit: The company achieved a gross profit of $698,231 for the three months ended September 30, 2025, and $2,668,854 for the nine months ended September 30, 2025, indicating improved profitability from higher sales volumes.

Income (Loss) from Operations: The company reported an operating loss of $(8,782) for the three months ended September 30, 2025, but a positive income of $875,720 for the nine months ended September 30, 2025, showing a positive trend in operational efficiency over the nine-month period.

Net Income (Loss): BioScience Health Innovations recorded a net loss of $(8,782) for the three months ended September 30, 2025, and a net income of $875,720 for the nine months ended September 30, 2025, demonstrating a substantial increase in profitability year-over-year.

Net Loss Per Common Share - Basic: The net loss per common share was $(0.00) for the three months ended September 30, 2025, and $0.08 for the nine months ended September 30, 2025, reflecting the company's improved financial performance.

Business Highlights

Corporate Rebranding: The company has rebranded from Nowtransit to BioScience Health Innovations Inc., aligning its name with its strategic focus on advanced health science innovations.

Intellectual Property Development: BioScience Health Innovations has six patents pending, including the MODS Max (Mineral Oxide Delivery System) platform, which is expected to provide 5-10 years of market exclusivity.

New Product Launches: The company is actively marketing new products such as Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, and ADHD 365 maximum strength brain support.

MODS Max Technology Platform: This flagship technology enhances absorption, provides broad-spectrum antimicrobial activity, and offers superior stability, addressing multiple high-growth healthcare segments.

Strategic Partnerships: BioScience Health Innovations is pursuing partnerships aligned with the MODS Max platform, attracting interest from the supplement/pharmaceutical sector and clinical compounding pharmacy channels.

Market Opportunities: The company is targeting several high-growth markets, including oral GLP-1 agonists, testosterone replacement therapy, and transmucosal drug delivery.

Operational Execution: The company is focusing on capital-efficient, high-margin growth through direct-to-consumer channels, supported by web subscriptions and targeted online marketing campaigns.

Future Outlook: Management is committed to innovation-led growth and regulatory progress, positioning the company for sustainable long-term expansion in both US and global markets.

SEC Filing: BioScience Health Innovations, Inc. [ BHIC ] - 10-Q - Oct. 27, 2025